source
- ArriVent shares tumble as lung cancer trial of furmonertinib misses primary goalArriVent BioPharma reported that its late-stage study of furmonertinib in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer did not achieve its primary endpoint. The trial, w…
- Key Biopharma Conferences to Watch in 2027 Highlight Industry TrendsThe article lists major medical meetings slated for 2027 that serve as platforms for companies to present clinical data and network. Highlights include the J.P. Morgan Healthcare Conference in ear…